The primary endpoint is objective response rate, with progression-free survival a key secondary endpoint. The study includes a pre-registration step for arm determination by the molecular tumor board.

Darolutamide may offer greater benefits than enzalutamide or apalutamide for Black and White patients with non-metastatic ...

Real-world data highlight gaps in genetic testing and targeted therapy use for metastatic castration-resistant prostate ...

Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to ...

Cade, Telix Group Chief Medical Officer, said, “Telix will feature in four presentations at this year’s ASCO GU, which showcase the depth and differentiation of our therapeutic urologic pipeline, ...

Advanced Ovarian Cancer Pipeline Insights LAS VEGAS, NV, UNITED STATES, February 12, 2025 /EINPresswire / -- As per DelveInsight's assessme ...

First real-world outcomes data for ADSTILADRIN® (nadofaragene firadenovec-vncg) to be presented at 2025 ASCO Genitourinary ...

New, less damaging treatments are giving some patients the choice to try to preserve their ability to have children after ...

The municipality commemorated World Cancer Day with the reading of a Manifesto and the presentation of the poster for the ...

Northwest Radon Poster Contest is underway, inviting students aged 9 to 14 from Idaho, Washington, and Oregon to create posters that raise awareness a ...

WACO, Texas (KWTX) - A respected and admired Central Texas fundraiser who is battling terminal cancer didn’t let that or a recent neck injury that required emergency surgery just days ago keep him ...

Flatiron Health today announced its planned presence at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), including ...